Skip to main content
. 2016 Oct 5;5(1):1719. doi: 10.1186/s40064-016-3404-x

Fig. 2.

Fig. 2

Cost-effectiveness frontier a without renal impact and b including renal impact. ADV adefovir dipivoxil, BSC best supportive care, CE cost-effectiveness, ETV entecavir, LAM lamivudine, LDT telbivudine, QALY quality-adjusted life-year, TDF tenofovir